Skip to main content
. 2014 Sep 30;14(3):164–172. doi: 10.5230/jgc.2014.14.3.164

Fig. 5.

Fig. 5

Overall survival of patients receiving zoledronic acid after developing bone metastasis. OS-BM = overall survival after developing bone metastasis.